Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized,placebo‐controlled phase 3 trial |
| |
| Authors: | Masatoshi Abe Chikako Nishigori Hideshi Torii Hironobu Ihn Kei Ito Makoto Nagaoka Naoki Isogawa Isao Kawaguchi Yukiko Tomochika Mihoko Kobayashi Anna M. Tallman Kim A. Papp |
| |
| Affiliation: | 1. Sapporo Skin Clinic, Sapporo, Japan;2. Division of Dermatology, Kobe University, Kobe, Japan;3. Division of Dermatology, Tokyo Yamate Medical Center, Tokyo, Japan;4. Kumamoto University, Kumamoto, Japan;5. JR Sapporo Hospital, Sapporo, Japan;6. Pfizer Japan Inc, Tokyo, Japan;7. Pfizer Inc, New York, USA;8. Probity Medical Research and K. Papp Clinical Research Inc., Waterloo, Ontario, Canada |
| |
| Abstract: | Tofacitinib is an oral Janus kinase inhibitor. These post‐hoc analyses assessed tofacitinib efficacy and safety in Japanese patients with psoriasis enrolled in a 52‐week global phase 3 study. Patients received tofacitinib 5 mg, tofacitinib 10 mg or placebo twice daily (b.i.d.); placebo‐treated patients advanced to tofacitinib at week 16. Primary efficacy end‐points were the proportions of patients with 75% or more reduction from baseline Psoriasis Area and Severity Index (PASI‐75) and Physician's Global Assessment (PGA) of “clear” or “almost clear” (PGA response) at week 16. Other end‐points included: Itch Severity Item (ISI), Dermatology Life Quality Index (DLQI) score and Nail Psoriasis Severity Index (NAPSI). Adverse events (AEs) were recorded throughout the study. Overall, 58 Japanese patients were included in this analysis (tofacitinib 5 mg b.i.d., n = 22; 10 mg b.i.d., n = 24; placebo, n = 12); 29 completed the study. At week 16, significantly more patients receiving tofacitinib 5 and 10 mg b.i.d. versus placebo achieved PASI‐75 (50% and 75% vs 0%, P < 0.01) and PGA response (59% and 75% vs 0%, P < 0.001). Substantial improvements in ISI, DLQI and NAPSI score were observed with both tofacitinib doses. Over 52 weeks, similar rates of AEs were reported across treatment groups; one serious AE occurred with tofacitinib 10 mg b.i.d. Herpes zoster occurred in three patients receiving tofacitinib 10 mg b.i.d. No deaths, serious infections, malignancies or gastrointestinal perforations were reported. Results were generally consistent with global analysis, suggesting sustained efficacy and a manageable safety profile, with increased herpes zoster incidence, of tofacitinib in Japanese patients with psoriasis. |
| |
| Keywords: | Janus kinase inhibitor Japanese oral medicine plaque psoriasis tofacitinib |
|
|
